The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …

Simple Summary Despite recent advances in surgical techniques and in anticancer drugs,
and the adoption of perioperative treatments mostly based on conventional chemotherapy …

Purpose: To demonstrate the negative prognostic impact of a panel of genomic alterations
(PRESSING-HER2 panel) and lack of HER2 amplification by next-generation sequencing …

Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not
significantly improve survival of patients with HER2-positive metastatic gastric cancer …

Simple Summary Early detection and personalized treatment for breast cancer are vital for
breast cancer patients survival. Computational pathology approaches can be employed by …

Enhanced knowledge of the interaction of cancer cells with their environment elucidated the
critical role of tumor microenvironment in tumor progression and chemoresistance. Cancer …

Gastric cancer (GC), a highly heterogeneous disease, has diverse histological and
molecular subtypes. For precision medicine, well‑characterized models encompassing the …

Purpose Trastuzumab is an HER2-specific agent approved as the gold-standard therapy for
advanced HER2-positive (HER2+) gastric cancer (GC), but the high rate and rapid …

Purpose IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different
malignancies, particularly in the development and malignant progression of lymphocytes …

Biomarkers in Gastric Cancer: This review focus into the recent advancements in the
identification and application of biomarkers for gastric cancer, exploring their pivotal role in …